emendrixAccount

Provision history · IVDR

Annex III · TECHNICAL DOCUMENTATION ON POST-MARKET SURVEILLANCE

In Vitro Diagnostic Medical Devices Regulation · 32017R0746 · every version of this act · on EUR-Lex (external, EUR-Lex)

1 change recorded across 1 version, newest first.

Twin in Medical Devices Regulation: Annex III, textually similar (0.950), paired on this act's text of 10 January 2025 and the Medical Devices Regulation text of 19 July 2026. See where the two texts differ.

Follow this provision (Atom) · Watch it from CI · Watch this provision

Version detected , Modified +9 −6

no amending act named

Applies from: no date changed

Explanation, written by a model and checked against the cited text

In section 1(b), the phrase describing what the trend report methods and protocols manage was changed from referring to 'events' to referring to 'incidents'.

Cited: Annex III, v1 (external, EUR-Lex) · Annex III, v2 (external, EUR-Lex)

v1 is the previous version, v2 this one.

Text from EUR-Lex, before and after

Previous version 32017R0746 → this version, detected 12 August 2026 02017R0746-20170505

ANNEX III TECHNICAL DOCUMENTATION ON POST-MARKET SURVEILLANCE The technical documentation on post-market surveillance to be drawn up by the manufacturer in accordance with Articles 78 to 81 shall be presented in a clear, organised, readily searchable and unambiguous manner and shall include in particular the elements described in this Annex. 1. The post-market surveillance plan drawn up in accordance with Article 79. The manufacturer shall prove in a post-market surveillance plan that it complies with the obligation referred to in Article 78. (a) The post-market surveillance plan shall address the collection and utilisation of available information, in particular: information concerning serious incidents, including information from PSURs, and field safety corrective actions, records referring to non-serious incidents and data on any undesirable side-effects, information from trend reporting, relevant specialist or technical literature, databases and/or registers, information, including feedbacks and complaints, provided by users, distributors and importers, and publicly-available information about similar medical devices. (b) The post-market surveillance plan shall cover at least: a proactive and systematic process to collect any information referred to in point (a). The process shall allow a correct characterisation of the performance of the devices and shall also allow a comparison to be made between the device and similar products available on the market; effective and appropriate methods and processes to assess the collected data; suitable indicators and threshold values that shall be used in the continuous reassessment of the benefit-risk analysis and of the risk management as referred to in Section 3 of Annex I; effective and appropriate methods and tools to investigate complaints and analyse market-related experience collected in the field; methods and protocols to manage the events incidents subject to the trend report as provided for in Article 83, including the methods and protocols to be used to establish any statistically significant increase in the frequency or severity of incidents as well as the observation period; methods and protocols to communicate effectively with competent authorities, notified bodies, economic operators and users; reference to procedures to fulfil the manufacturers obligations laid down in Articles 78, 79 and 81; systematic procedures to identify and initiate appropriate measures including corrective actions; effective tools to trace and identify devices for which corrective actions might be necessary; and a PMPF plan as referred to in Part B of Annex XIII, or a justification as to why a PMPF is not applicable. 2. The PSUR referred to in Article 81 and the post-market surveillance report referred to in Article 80.